Why Iovance Biotherapeutics (IOVA) Shares Are Exploding Higher
Portfolio Pulse from Henry Khederian
Iovance Biotherapeutics Inc's shares are trading higher by 14.3% after the company announced positive regulatory and clinical updates for its Phase 2 IOV-LUN-202 trial in post-anti-PD-1 non-small cell lung cancer (NSCLC). The FDA provided favorable feedback on the trial design, indicating potential accelerated approval for LN-145 TIL therapy. The company plans to enroll around 120 patients and expects enrollment to be completed by the second half of 2024.
July 10, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics Inc's stock price is likely to increase in the short term due to positive regulatory and clinical updates for its Phase 2 IOV-LUN-202 trial in NSCLC.
The company's shares are trading higher following the announcement of positive regulatory and clinical updates for its Phase 2 IOV-LUN-202 trial in NSCLC. The FDA's favorable feedback on the trial design, indicating potential accelerated approval for LN-145 TIL therapy, is a significant positive development for the company and is likely to boost investor confidence, leading to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100